Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

2014137 citationsJournal Article

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 25, Issue 12, pp. 2363-2372

Field-Weighted Citation Impact: 6.34